These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32022786)

  • 21. Icosapent ethyl: scientific and legal controversies.
    Curfman G; Shehada E
    Open Heart; 2021 Apr; 8(1):. PubMed ID: 33888593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides.
    Pareek M; Mason RP; Bhatt DL
    Expert Opin Drug Saf; 2022 Jan; 21(1):31-42. PubMed ID: 34253137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
    Vijayaraghavan K; Szerlip HM; Ballantyne CM; Bays HE; Philip S; Doyle RT; Juliano RA; Granowitz C
    Postgrad Med; 2019 Aug; 131(6):390-396. PubMed ID: 31306043
    [No Abstract]   [Full Text] [Related]  

  • 24. Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date.
    Jia X; Koh S; Al Rifai M; Blumenthal RS; Virani SS
    Vasc Health Risk Manag; 2020; 16():1-10. PubMed ID: 32021223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction.
    Boden WE; Baum S; Toth PP; Fazio S; Bhatt DL
    Future Cardiol; 2021 Jan; 17(1):155-174. PubMed ID: 32959713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
    Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective.
    Gao L; Moodie M; Li SC
    Eur J Intern Med; 2019 Sep; 67():70-76. PubMed ID: 31285124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
    Scherer DJ; Nicholls SJ
    Vasc Health Risk Manag; 2015; 11():203-9. PubMed ID: 25848301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
    J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isosapent ethyl (Vascepa) for severe hypertriglyceridemia.
    Med Lett Drugs Ther; 2013 Apr; 55(1415):33-4. PubMed ID: 23836343
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of icosapent ethyl on stroke risk: Different strokes for different folks?
    Lee M; Ovbiagele B
    J Neurol Sci; 2019 Jun; 401():127. PubMed ID: 31077950
    [No Abstract]   [Full Text] [Related]  

  • 32. JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes.
    Bittner VA; Jacobson TA; Ballantyne CM; Guyton JR
    J Clin Lipidol; 2020; 14(1):4-15. PubMed ID: 32192643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
    Bays HE; Tighe AP; Sadovsky R; Davidson MH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):391-409. PubMed ID: 18327998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future.
    Perez-Martinez P; Katsiki N; Mikhailidis DP
    Angiology; 2020 Jan; 71(1):10-16. PubMed ID: 30966756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials.
    Jia X; Kohli P; Virani SS
    Curr Atheroscler Rep; 2019 Jan; 21(1):1. PubMed ID: 30631963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.
    Reddy KJ; Chowdhury S
    Future Cardiol; 2016 May; 12(3):261-8. PubMed ID: 27070379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT.
    Gaba P; Bhatt DL; Mason RP; Miller M; Verma S; Steg PG; Boden WE;
    J Clin Lipidol; 2022; 16(4):389-402. PubMed ID: 35773147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).
    Braeckman RA; Manku MS; Bays HE; Stirtan WG; Soni PN
    Prostaglandins Leukot Essent Fatty Acids; 2013 Sep; 89(4):195-201. PubMed ID: 23992935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk.
    Dixon DL
    Am J Med; 2020 Jul; 133(7):802-804. PubMed ID: 32243872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omega-3 fatty acids for cardiovascular event lowering.
    Kaur G; Mason RP; Steg PG; Bhatt DL
    Eur J Prev Cardiol; 2024 Jun; 31(8):1005-1014. PubMed ID: 38169319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.